ATXA is focusing on late-stage preclinical & clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension.
ATXA Therapeutics has raised $21.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2022.
ATXA Therapeutics's investors include Enterprise Ireland, European Innovation Council, EISMEA.
ATXA Therapeutics is headquartered in Blackrock, Ireland.
ATXA is focusing on late-stage preclinical & clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension.
ATXA Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ATXA Therapeutics — Funding & Investors." VCBacked, October 21, 2022, https://www.vcbacked.co/company/atxa-therapeutics. Accessed August 15, 2026.
VCBacked. (2022). ATXA Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/atxa-therapeutics
{{cite web |title=ATXA Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/atxa-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated